論文

査読有り 国際誌
2020年10月7日

Expression status of PD-L1 and B7-H3 in mesothelioma.

Pathology international
  • Eiji Matsumura
  • ,
  • Kazunori Kajino
  • ,
  • Masaaki Abe
  • ,
  • Naomi Ohtsuji
  • ,
  • Harumi Saeki
  • ,
  • May Thinzar Hlaing
  • ,
  • Okio Hino

記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/pin.13028

Mesothelioma is a rare, aggressive malignancy with poor outcome, and has limited treatment options. The aim of this study was to perform a comprehensive analysis of programmed death ligand 1 (PD-L1) and B7 homolog 3 (B7-H3) expression in mesothelioma. We investigated the protein expression of PD-L1 and B7-H3 and their potential correlation with histological subtype, which might help to develop new therapies targeting these immune checkpoint molecules. Expression analysis of PD-L1 and B7-H3 was performed by immunohistochemistry using serial tissue sections of specimens obtained from 31 patients with mesothelioma. Tumors were classified into 22 epithelioid, 6 sarcomatoid, and 3 biphasic types. Of the 31 patients, 13 (41.9%) were positive for PD-L1 and 28 (90.3%) were B7-H3 positive. Twelve of the 13 PD-L1 positive patients were positive for B7-H3. PD-L1 and B7-H3 were widely co-expressed in biphasic and sarcomatoid type tumor cells. These findings might provide a rationale for the use of combination therapy for mesothelioma by targeting PD-L1 and B7-H3, as well as the development of anti-B7-H3 or anti-PD-L1 single agents.

リンク情報
DOI
https://doi.org/10.1111/pin.13028
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33027549

エクスポート
BibTeX RIS